collaborations with various North American and European pharmaceutical partners. We have also produced over 350 commercial antibodies and submitted several patents for our technologies. In 2015, they took the bold step of initiating their own antibody pipeline, with a primary focus on cancer and gastrointestinal health. Thus far we have advanced 4 candidates to late stages of discovery.